Float Short %

7.87

Margin Of Safety %

Put/Call OI Ratio

0.82

EPS Next Q Diff

-0.03

EPS Last/This Y

-1.96

EPS This/Next Y

-0.99

Price

101.82

Target Price

121.94

Analyst Recom

Performance Q

44.28

Upside

-166.1%

Beta

0.99

Ticker: RVMD

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	RVMD	117.69	0.47	0.18	114772
2026-01-26	RVMD	97.65	0.46	0.60	116959
2026-01-27	RVMD	99.62	0.46	1.68	122361
2026-01-28	RVMD	97.36	0.45	0.55	118460
2026-01-29	RVMD	98.21	0.45	0.10	120367
2026-01-30	RVMD	96.92	0.43	0.47	124889
2026-02-02	RVMD	97.16	0.43	3.50	125034
2026-02-03	RVMD	96	0.46	4.63	128711
2026-02-05	RVMD	96.16	0.49	1.81	131390
2026-02-09	RVMD	96.75	0.51	19.89	137576
2026-02-10	RVMD	95.88	0.61	17.26	147568
2026-02-11	RVMD	97.63	0.69	0.28	154824
2026-02-12	RVMD	97.24	0.72	0.37	157664
2026-02-13	RVMD	96.21	0.72	0.09	158724
2026-02-17	RVMD	100.6	0.71	7.28	160031
2026-02-18	RVMD	99.78	0.75	2.56	164984
2026-02-19	RVMD	102.64	0.76	0.94	166748
2026-02-20	RVMD	101.74	0.82	0.21	172812
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	RVMD	117.63	-39.8	-250.6	-5.54
2026-01-26	RVMD	97.71	-39.8	-25.4	-5.54
2026-01-27	RVMD	99.77	-39.8	-293.9	-5.54
2026-01-28	RVMD	97.33	-39.8	-228.9	-5.54
2026-01-29	RVMD	98.20	-39.8	-277.3	-5.54
2026-01-30	RVMD	96.93	-39.8	-245.9	-5.54
2026-02-02	RVMD	97.16	-39.8	-268.8	-5.54
2026-02-03	RVMD	95.94	-39.8	-246.6	-5.54
2026-02-04	RVMD	96.46	-39.8	-271.1	-5.54
2026-02-05	RVMD	96.13	-39.8	-259.0	-5.54
2026-02-06	RVMD	97.46	-39.8	-284.6	-5.54
2026-02-09	RVMD	96.75	-39.8	-253.7	-5.54
2026-02-10	RVMD	95.78	-39.8	-250.3	-5.54
2026-02-11	RVMD	97.97	-39.8	-294.5	-5.54
2026-02-12	RVMD	97.34	-39.8	-255.5	-5.54
2026-02-13	RVMD	96.19	-39.8	-247.8	-5.54
2026-02-17	RVMD	100.56	-39.2	-327.2	-5.54
2026-02-18	RVMD	99.79	-39.2	-253.3	-5.54
2026-02-19	RVMD	102.66	-39.2	-	-5.54
2026-02-20	RVMD	101.82	-39.2	-	-5.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	RVMD	-1.66	2.01	9.26
2026-01-26	RVMD	-1.66	2.06	9.26
2026-01-27	RVMD	-1.66	2.06	9.26
2026-01-28	RVMD	-1.66	2.06	8.60
2026-01-29	RVMD	-1.66	2.06	8.60
2026-01-30	RVMD	-1.66	2.06	8.60
2026-02-02	RVMD	-1.66	2.00	8.60
2026-02-03	RVMD	-1.66	2.00	8.60
2026-02-04	RVMD	-1.66	2.00	8.60
2026-02-05	RVMD	-1.66	2.00	8.60
2026-02-06	RVMD	-1.66	2.00	8.60
2026-02-09	RVMD	-1.66	2.99	8.60
2026-02-10	RVMD	-1.66	2.99	8.60
2026-02-11	RVMD	-1.66	2.99	7.91
2026-02-12	RVMD	-1.66	2.99	7.91
2026-02-13	RVMD	-1.66	2.99	7.91
2026-02-17	RVMD	-1.66	3.89	7.91
2026-02-18	RVMD	-1.66	3.89	7.91
2026-02-19	RVMD	-1.71	3.89	7.87
2026-02-20	RVMD	-1.71	3.89	7.87
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.61

Avg. EPS Est. Current Quarter

-1.6

Avg. EPS Est. Next Quarter

-1.64

Insider Transactions

-1.71

Institutional Transactions

3.89

Beta

0.99

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

18.2

Max Drawdown 5-Year %

-70.6

Target Price

121.94

P/E

Forward P/E

PEG

P/S

P/B

12.1

P/Free Cash Flow

EPS

-5.18

Average EPS Est. Cur. Y

-5.54

EPS Next Y. (Est.)

-6.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.51

Return on Equity vs Sector %

-89.2

Return on Equity vs Industry %

-71.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Revolution Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 809

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today

news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance

stock history RVMD – Revolution Medicines, Inc. invest stock market

stock prices RVMD premarket after hours

ticker RVMD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RVMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y